Explore /
Poster
/ Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.

Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.

Authors

Panayiotis Vandris

Stanford University School of Medicine, Stanford, CA

Panayiotis Vandris , Karen Chao , Christina Baggott , Christine L. Phillips , Muna Qayed , Jenna Rossoff , Stephanie J. Si Lim , Lena E. Winestone , Heather E. Stefanski , Julie-An M. Talano , Steven Margossian , Michael R. Verneris , Gary Douglas Myers , Nicole A. Karras , Patrick A. Brown , Prakash Satwani , Crystal Mackall , Kevin J. Curran , Theodore Willis Laetsch , Liora M. Schultz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Leukemia/Lymphoma

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10016)

DOI

10.1200/JCO.2022.40.16_suppl.10016

Abstract #

10016

Poster Bd #

231

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

$Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.$